hVIVO plc (Euronext / LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:
| Title | Challenge Studies – can the results be expected to mimic field trial data? |
| Date/Time | Wednesday 5 April 2023, 17.10 (ET) |
The World Vaccine Congress will take place at the Walter E. Washington Convention Center in Washington D.C. between 3-6 April 2023. hVIVO will be at booth 813 during the congress for potential partnering discussions.
The World Vaccine Congress, organised by Terrapin, is the largest and most established meeting dedicated to vaccines and has run for 23 years. From basic research to commercial manufacture, the event covers the whole vaccine value chain, with hundreds of speakers and thousands of attendees from leading global vaccines developers, academia and policymakers.
More information about the event, including attendance, can be found here.
To request meetings with hVIVO at the World Vaccine Congress, interested parties should register with Swapcard and use the following link or by emailing [email protected]
Yamin ‘Mo’ Khan, Chief Executive Officer at hVIVO, said: “I am delighted that Andrew will be presenting at the largest vaccine event of the year amongst many other notable speakers, discussing the significant value of human challenge trial data. As the global leader in conducting human challenge trials to test vaccines and antivirals for infectious and respiratory diseases, we are looking forward to participating in roundtable discussions and sharing insights into how human challenge trials can accelerate the drug development process.”
